Fig. 2From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinomaOverall survival (OS) and progression-free survival (PFS) curves of patients with metastatic renal cell carcinoma with and without post-treatment hypoalbuminemia who received sorafenib or sunitinib as first-line therapy. In the post-treatment hypoalbuminemia group, OS (a) and PFS (b) rates are significantly lower than those in the normal post-treatment albumin level groupBack to article page